Intra-Cellular Therapies
ITCI
#1827
Rank
NZ$15.64 B
Marketcap
$147.56
Share price
-0.82%
Change (1 day)
39.27%
Change (1 year)

Revenue for Intra-Cellular Therapies (ITCI)

Revenue in 2024 (TTM): NZ$0.99 Billion

According to Intra-Cellular Therapies's latest financial reports the company's current revenue (TTM ) is NZ$1.08 Billion. In 2023 the company made a revenue of NZ$0.73 Billion an increase over the revenue in the year 2022 that were of NZ$0.39 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Intra-Cellular Therapies from 2014 to 2024

Annual revenue

Year Revenue Change
2024 (TTM) NZ$0.99 B35.64%
2023 NZ$0.73 B86.25%
2022 NZ$0.39 B228.02%
2021 NZ$0.11 B283.09%
2020 NZ$31.22 M34595.48%
2019 NZ$0.09 M
2018 N/A
2017 N/A
2016 N/A-100%
2015 NZ$0.04 M-93.59%
2014 NZ$0.69 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$18.13 M-98.33%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$0.15 B-86.10%๐Ÿ‡บ๐Ÿ‡ธ USA